Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients

Transplantation

Volumn 81, Issue 9, 2006, Pages 1227-1233

  Opelz, Gerhard ^a   Naujokat, Cord ^a   Daniel, Volker ^a   Terness, Peter ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS;

ANTILYMPHOCYTE SERUM; DATABASES, FACTUAL; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MUROMONAB-CD3; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT FAILURE;

EID: 33744457937     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000219817.18049.36     Document Type: Article

References (25)

1. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
2. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198.
3. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165.
4. Ponticelli C, Yussim C, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-1267.
5. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37-43.
6. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110-115.
7. Kahan BD, Rajagopalan PR, Hall M, et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276-284.
8. Meier-Kriesche H-U, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
9. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516.
10. Opelz G, Döhler B. Lymphomas after solid organ transplantation: A Collaborative Transplant Study Report. Am J Transplant 2003; 4: 222-230.
11. International Association of Cancer Registries. Parkin DM, Whelan SL, Ferlay J, et al., eds. Cancer incidence in five continents, vol. VIII. Lyons, France, IARC Press, 2002.
12. Liddell FDK. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 1984; 38: 85-88.
13. Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
14. Brennan DC, The Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: Final results from a prospective, randomized, multicenter trial. Am J Transplant 2003; 76(suppl 4): 438.
15. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78: 136-141.
16. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293.
17. Ekberg H, Backman L, Tufveson G, et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13: 151-159.
18. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003; 326: 789-784.
19. Chapman TM, Keating GM. Basiliximab: A review or its use as induction therapy in renal transplantation. Drugs 2003; 63: 2803-2835.
20. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77: 1029-1033.
21. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194-1200.
22. Kung PC, Goldstein G, Reinherz EL, et al. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347-349.
23. Chatenoud L. CD3-specific antibody-induced active tolerance: From bench to bedside. Nat Rev Immunol 2003: 123-132.
24. Baan CC, van Riemsdijk-Overbeeke IC, Boelaars-van Haperen MJ, et al. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol 2002; 10: 81-87.
25. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.